Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial

Blood (2022) 139 (15): 2306–2315.

https://doi.org/10.1182/blood.2021014738

Published: 2022

Includes: Supplemental data

Journal Articles

Impact of Center Experience with Donor Type and Treatment Platform on Outcomes: A Secondary Analysis BMT CTN 1101

Blood (2021) 138 (Supplement 1): 3956.

https://doi.org/10.1182/blood-2021-145527

Published: 2021

Journal Articles

Tisagenlecleucel Demonstrates Safety, Efficacy and CNS Trafficking in Primary CNS Lymphoma

Blood (2021) 138 (Supplement 1): 258.

https://doi.org/10.1182/blood-2021-148444

Published: 2021

Journal Articles

Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial

Ephraim J. Fuchs, Paul V. O’Donnell, Mary Eapen, Brent Logan, Joseph H. Antin, Peter Dawson, Steven Devine, Mary M. Horowitz, Mitchell E. Horwitz, Chatchada Karanes, Eric Leifer, John M. Magenau, Joseph P. McGuirk, Lawrence E. Morris, Andrew R. Rezvani, Richard J. Jones, Claudio G. Brunstein

Blood (2021) 137 (3): 420–428.

https://doi.org/10.1182/blood.2020007535

Published: 2021

Includes: Supplemental data

Journal Articles

Post-Transplant Cyclophosphamide in Allogeneic Bone Marrow Transplantation for the Treatment of Benign Hematologic Diseases

Mark Leick, MD, Bradley Hunter, MD MPH, Zachariah Defilipp, MD, Bimalangshu Dey, MD, Areej El-Jawahri, MD, Matthew J. Frigault, MD, Steven L McAfee, MD, Thomas Spitzer, MD, Paul V. O'Donnell, MD PhD, Yi-Bin Chen

Blood (2019) 134 (Supplement_1): 1978.

https://doi.org/10.1182/blood-2019-128295

Published: 2019

Journal Articles

Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure

Yi-Bin Chen, Nahel Elias, Eliot Heher, Jeannine S. McCune, Kerry Collier, Shuli Li, Candice Del Rio, Areej El-Jawahri, Winfred Williams, Nina Tolkoff-Rubin, Jay A. Fishman, Steven McAfee, Bimalangshu R. Dey, Zachariah DeFilipp, Paul V. O’Donnell, A. Benedict Cosimi, David Sachs, Tatsuo Kawai, Thomas R. Spitzer

Blood (2019) 134 (2): 211–215.

https://doi.org/10.1182/blood.2019000775

Published: 2019

Journal Articles

Bone Marrow Transplant Product Quality Has Decreased Over Time— a Retrospective Examination of NMDP Collected Bone Marrow Products from 1994-2016

Nicole L. Prokopishyn, PhD, Deidre M. Kiefer, MPH, Michael A Pulsipher, MD, Galen E. Switzer, PhD, Nirali N Shah, MD, Paul V. O'Donnell, MD PhD, Brent R. Logan, PhD, Dennis L. Confer, MD, Bronwen E. Shaw, PhD MRCP, FRCPath

Blood (2017) 130 (Supplement 1): 1921.

https://doi.org/10.1182/blood.V130.Suppl_1.1921.1921

Published: 2017

Journal Articles

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide

Blood (2017) 129 (10): 1389–1393.

https://doi.org/10.1182/blood-2016-09-737825

Published: 2017

Includes: Supplemental data

Journal Articles

Comparison of Peripheral Blood Stem Cells (PBSC) to Bone Marrow (BM) for T-Replete HLA-Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide

Blood (2016) 128 (22): 683.

https://doi.org/10.1182/blood.V128.22.683.683

Published: 2016

Journal Articles

Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation

Marco Mielcarek, Terry Furlong, Paul V. O’Donnell, Barry E. Storer, Jeannine S. McCune, Rainer Storb, Paul A. Carpenter, Mary E. D. Flowers, Frederick R. Appelbaum, Paul J. Martin

Blood (2016) 127 (11): 1502–1508.

https://doi.org/10.1182/blood-2015-10-672071

Published: 2016

Includes: Supplemental data

Journal Articles

Analysis of Pre-Transplant Therapy with Brentuximab Vedotin for Relapsed/Refractory Hodgkin Lymphoma on Outcomes of Reduced Intensity Conditioned Allogeneic Hematopoietic Cell Transplantation

Baldeep Wirk, MD, Barry E. Storer, PhD, David G Maloney, MD PhD, Ajay K Gopal, MD, Ryan D Cassaday, MD, Rachel Salit, MD, Paul V. O'Donnell, MD PhD, Brenda M. Sandmaier, MD, Mary E.D. Flowers, MD

Blood (2015) 126 (23): 4406.

https://doi.org/10.1182/blood.V126.23.4406.4406

Published: 2015

Journal Articles

Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Primary Refractory Acute Myeloid Leukemia

Sarita Rani Jaiswal, MD BSc, Sumita Chatterjee, MSc, Aditi Chakrabarti, Sneh Bhargava, Ray Kunal, Suparno Chakrabarti, MD FRCPath, Paul V. O'Donnell, MD PhD

Blood (2015) 126 (23): 4411.

https://doi.org/10.1182/blood.V126.23.4411.4411

Published: 2015

Journal Articles

Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia

Blood (2015) 126 (8): 1033–1040.

https://doi.org/10.1182/blood-2015-04-639831

Published: 2015

Includes: Supplemental data

Journal Articles

211 At-Anti-CD45 Radioimmunotherapy Can Replace TBI Prior to Haploidentical Bone Marrow Transplantation and Yield Long-Term Hematopoietic Engraftment

Johnnie J. Orozco, MD PhD, Aimee L. Kenoyer, BS, Ethan R. Balkin, PhD, Donald K. Hamlin, BS, D Scott Wilbur, PhD, Sofia H.L. Frost, PhD, Mark D. Hylarides, PhD, Damian J. Green, MD, Ajay K. Gopal, MD, Brenda M. Sandmaier, MD, Oliver W. Press, MD PhD, Paul V. O'Donnell, MD PhD, John M. Pagel, MD PhD

Blood (2014) 124 (21): 2417.

https://doi.org/10.1182/blood.V124.21.2417.2417

Published: 2014

Journal Articles

Posttransplant Cyclophosphamide for Prevention of Graft-Versus-Host Disease after HLA-Matched Related and Unrelated Donor Peripheral Blood Stem Cell Transplantation

Marco Mielcarek, MD, Terrence Furlong, Paul V. O'Donnell, MD PhD, Barry E. Storer, PhD, Rainer F. Storb, MD, Paul A. Carpenter, MD, Paul J. Martin, MD

Blood (2014) 124 (21): 1161.

https://doi.org/10.1182/blood.V124.21.1161.1161

Published: 2014

Journal Articles

Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation

Michael A. Pulsipher, Pintip Chitphakdithai, Brent R. Logan, Willis H. Navarro, John E. Levine, John P. Miller, Bronwen E. Shaw, Paul V. O’Donnell, Navneet S. Majhail, Dennis L. Confer

Blood (2014) 123 (23): 3655–3663.

https://doi.org/10.1182/blood-2013-12-542464

Published: 2014

Includes: Supplemental data

Journal Articles

Influence Of Race and Ethnicity On The Collection Of G-CSF Mobilized Peripheral Blood Stem Cells From Unrelated Donors, a Center For International Blood and Marrow Transplant Research Analysis

Jack W. Hsu, MD, John R. Wingard, MD, PhD, Brent R. Logan, PhD, Pintip Chitphakdithai, PhD, Bronwen E. Shaw, MBChB, MRCP, PhD, FRCPath, Steven C. Goldstein, MD, Paul V. O’Donnell, MD, PhD, FACP, Dennis L. Confer, MD

Blood (2013) 122 (21): 3273.

https://doi.org/10.1182/blood.V122.21.3273.3273

Published: 2013

Journal Articles

Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program

Blood (2013) 121 (1): 197–206.

https://doi.org/10.1182/blood-2012-03-417667

Published: 2013

Includes: Supplemental data

Journal Articles

Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts

Claudio G. Brunstein, Ephraim J. Fuchs, Shelly L. Carter, Chatchada Karanes, Luciano J. Costa, Juan Wu, Steven M. Devine, John R. Wingard, Omar S. Aljitawi, Corey S. Cutler, Madan H. Jagasia, Karen K. Ballen, Mary Eapen, Paul V. O'Donnell, on behalf of the Blood and Marrow Transplant Clinical Trials Network

Blood (2011) 118 (2): 282–288.

https://doi.org/10.1182/blood-2011-03-344853

Published: 2011

Journal Articles

Practice patterns for evaluation, consent, and care of related donors and recipients at hematopoietic cell transplantation centers in the United States

Paul V. O'Donnell, Tanya L. Pedersen, Dennis L. Confer, J. Douglas Rizzo, Michael A. Pulsipher, David Stroncek, Susan Leitman, Paolo Anderlini

Blood (2010) 115 (24): 5097–5101.

https://doi.org/10.1182/blood-2010-01-262915

Published: 2010

Includes: Supplemental data

NARROW

Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial

Impact of Center Experience with Donor Type and Treatment Platform on Outcomes: A Secondary Analysis BMT CTN 1101

Tisagenlecleucel Demonstrates Safety, Efficacy and CNS Trafficking in Primary CNS Lymphoma

Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial

Post-Transplant Cyclophosphamide in Allogeneic Bone Marrow Transplantation for the Treatment of Benign Hematologic Diseases

Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure

Bone Marrow Transplant Product Quality Has Decreased Over Time— a Retrospective Examination of NMDP Collected Bone Marrow Products from 1994-2016

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide

Comparison of Peripheral Blood Stem Cells (PBSC) to Bone Marrow (BM) for T-Replete HLA-Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide

Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation

Analysis of Pre-Transplant Therapy with Brentuximab Vedotin for Relapsed/Refractory Hodgkin Lymphoma on Outcomes of Reduced Intensity Conditioned Allogeneic Hematopoietic Cell Transplantation

Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Primary Refractory Acute Myeloid Leukemia

Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia

211 At-Anti-CD45 Radioimmunotherapy Can Replace TBI Prior to Haploidentical Bone Marrow Transplantation and Yield Long-Term Hematopoietic Engraftment

Posttransplant Cyclophosphamide for Prevention of Graft-Versus-Host Disease after HLA-Matched Related and Unrelated Donor Peripheral Blood Stem Cell Transplantation

Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation

Influence Of Race and Ethnicity On The Collection Of G-CSF Mobilized Peripheral Blood Stem Cells From Unrelated Donors, a Center For International Blood and Marrow Transplant Research Analysis

Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program

Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts

Practice patterns for evaluation, consent, and care of related donors and recipients at hematopoietic cell transplantation centers in the United States

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only